Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

被引：0

作者：

Monica N. Khattak

Anna M. Chichura

Julie E. Lang

机构：

[1] Cleveland Clinic Foundation,Division of Breast Services

来源：

Annals of Surgical Oncology | 2024年 / 31卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

This ASO perspective reviews the findings of a randomized, phase II clinical trial evaluating adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel and trastuzumab (TH) in stage I human epidermal growth factor receptor 2-positive breast cancer, as reported recently by the ATEMPT trial investigators. Patients treated with T-DM1 had better disease-free survival but did not have fewer treatment toxicities. The T-DM1-treated group had higher rates of treatment discontinuations, therefore long-term follow-up will be required to evaluate survival differences between T-DM1 and TH.

引用

页码：1423 / 1427

页数：4

共 50 条

[31] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting [J].

Shanshan Hu ;

Yilai Wu ;

Jiajie Luan ;

Shuowen Wang ;

Guorong Fan .

Journal of Cancer Research and Clinical Oncology, 2023, 149 :17933-17942

[32] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer [J].

Sonke, Gabe S. ;

Mandjes, Ingrid A. ;

Holtkamp, Marjo J. ;

Schot, Margaret ;

van Werkhoven, Erik ;

Wesseling, Jelle ;

Peeters, Marie-Jeanne Vrancken ;

Rodenhuis, Sjoerd ;

Linn, Sabine C. .

BREAST JOURNAL, 2013, 19 (04) :419-426

[33] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer [J].

Andrew D. Seidman ;

Larry Norton .

Current Oncology Reports, 2005, 7 (1) :9-11

[34] Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab [J].

Debien, Veronique ;

Agostinetto, Elisa ;

Sirico, Marianna ;

Jacobs, Flavia ;

Molinelli, Chiara ;

Moreau, Michel ;

Paesmans, Marianne ;

De Giorgi, Ugo ;

Santoro, Armando ;

Taylor, Donatienne ;

Duhoux, Francois P. ;

Botticelli, Andrea ;

Barchiesi, Giacomo ;

Lambertini, Matteo ;

de Azambuja, Evandro ;

Piccart, Martine .

CANCER RESEARCH, 2023, 83 (05)

[35] Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab [J].

Debien, Veronique ;

Marta, Guilherme Nader ;

Agostinetto, Elisa ;

Sirico, Marianna ;

Jacobs, Flavia ;

Molinelli, Chiara ;

Moreau, Michel ;

Paesmans, Marianne ;

De Giorgi, Ugo ;

Santoro, Armando ;

Taylor, Donatienne ;

Duhoux, Francois P. ;

Botticelli, Andrea ;

Barchiesi, Giacomo ;

Speranza, Iolanda ;

Lambertini, Matteo ;

Wildiers, Hans ;

de Azambuja, Evandro ;

Piccart, Martine .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 190

[36] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J].

Douchet, G. ;

Richard, Sandrine .

ONCOLOGIE, 2018, 20 (01) :43-44

[37] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[38] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer [J].

von Minckwitz, Gunter ;

Procter, Marion ;

de Azambuja, Evandro ;

Zardavas, Dimitrios ;

Benyunes, Mark ;

Viale, Giuseppe ;

Suter, Thomas ;

Arahmani, Amal ;

Rouchet, Nathalie ;

Clark, Emma ;

Knott, Adam ;

Lang, Istvan ;

Levy, Christelle ;

Yardley, Denise A. ;

Bines, Jose ;

Gelber, Richard D. ;

Piccart, Martine ;

Baselga, Jose .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02) :122-131

[39] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) [J].

Patel, Tejal A. ;

Ensor, Joe E. ;

Creamer, Sarah L. ;

Boone, Toniva ;

Rodriguez, Angel A. ;

Niravath, Poly A. ;

Darcourt, Jorge G. ;

Meisel, Jane L. ;

Li, Xiaoxian ;

Zhao, Jing ;

Kuhn, John G. ;

Rosato, Roberto R. ;

Qian, Wei ;

Belcheva, Anna ;

Schwartz, Mary R. ;

Kaklamani, Virginia G. ;

Chang, Jenny C. .

BREAST CANCER RESEARCH, 2019, 21 (01)

[40] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer [J].

Mariani, Gabriella ;

Fasolo, Angelica ;

De Benedictis, Elena ;

Gianni, Luca .

NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02) :93-104

← 1 2 3 4 5 →